CareDx Inc. (CDNA) reported earnings on Thur 28 Oct 21 (a/h)

•  For Q3, co posted upside results for EPS and for revs, which rose +42% yr/yr to $75.6 mln. Testing services volume grew +86% yr/yr. Raised its guidance for FY21 revs to $290-293 mln, in-line with estimates. Falls to 52-week lows. 

** charts after earnings **

 

CareDx beats by $0.05, beats on revs; raises FY21 revs in-line

• Reports Q3 (Sep) earnings of $0.07 per share, excluding non-recurring items, $0.05 better than the S&P Capital IQ Consensus of $0.02; revenues rose 41.6% year/year to $75.6 mln vs the $74.11 mln S&P Capital IQ Consensus.
• Co issues raised guidance for FY21, sees FY21 revs of $290-293 mln from $280-290 mln vs. $290.48 mln S&P Capital IQ Consensus.

CareDx Inc. (CDNA) reported earnings on Thur 9 Aug 2018 (a/h)

** charts before earnings **

 

** charts after earnings **

 

BRISBANE, Calif. (AP) _ CareDx Inc. (CDNA) on Thursday reported a loss of $14.1 million in its second quarter.

On a per-share basis, the Brisbane, California-based company said it had a loss of 40 cents. Losses, adjusted for non-recurring costs and stock option expense, were 4 cents per share.

The molecular diagnostics company posted revenue of $17.8 million in the period.

CareDx expects full-year revenue in the range of $68 million to $70 million.

CareDx shares have more than doubled since the beginning of the year. In the final minutes of trading on Thursday, shares hit $14.97, climbing tenfold in the last 12 months.

CareDx (CDNA) began trading on the Nasdaq on 17 July 2014

CareDx Announces Pricing of its IPO and Completion of its First Day of Trading

Brisbane, CA July 17, 2014 CareDx, Inc. (NASDAQ: CDNA) announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10 per share, before underwriter discounts. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price to cover over -allotments, if any. CareDx completed its first day of trading today on The NASDAQ Global Market under the ticker symbol "CDNA."

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Address

3260 Bayshore Blvd
BRISBANE, CA 94005-1021
United States